Efficacy of Retreatments With Intravitreal Bevacizumab

Phase 3

Terminated

• Conditions: Age Related Macular Degeneration; Choroidal Neovascularization

• Registration Number: NCT00406744
• Lead Sponsor: Asociación para Evitar la Ceguera en México

Brief Summary

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-05
• Primary Completion: 2006-05
• Study Completion: 2006-11
• Study First Submitted: 2006-11-30
• Study First Submitted QC: 2006-11-30
• Study First Posted: 2006-12-04
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-31
• Last Update Posted: 2024-06-03

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• * Any visual acuity

  • OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.
  • Active angiogram leakage

Exclusion Criteria

• * Basal Inflammatory disease

  • Endoftalmitis history
  • Lesions bigger than 5400 u or with scarring greater than 50% of lesion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram

Trial Locations

Locations (1)

Asociacion para Evitar la Ceguera en Mexico; 🇲🇽 Mexico DF, DF, Mexico